Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1/2 1Phase 1 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 12Breast 4Genitourinary 3Dermatologic 2Tumor-Agnostic 1Thoracic 1Sarcoma 1Other solid neoplasm 1Gynecologic 1CNS 1

Conditions

Resectable Localized Prostate Cancer 1Prostatic Neoplasms 1Prostate Cancer Recurrent 1Melanoma 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 182Magnetic Resonance Spectroscopy 161Specimen Handling 134enzalutamide 125Nivolumab 118Gemcitabine 96Docetaxel 92Radiosurgery 91Prednisone 81Androgen Antagonists 81Abiraterone Acetate 79Radiotherapy 75apalutamide 66Cisplatin 65darolutamide 62Ipilimumab 61Biopsy 61abiraterone 57cabozantinib 55Carboplatin 55Leuprolide 52enfortumab vedotin 50Radiation 47Pluvicto 45Standard of Care 44atezolizumab 41Surveys and Questionnaires 38acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 37X-Rays 37avelumab 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Hydroxychloroquine × Genitourinary × 1 year × Clear all
NCT05036226 2026-05-13

COAST

Medical University of South Carolina

Phase 1/2 Recruiting
76 enrolled
GenitourinaryOther solid neoplasm

Prostate Cancer Recurrent

NCT01480154 2026-04-13

Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
62 enrolled
DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma, Prostatic Neoplasms

NCT06408298 2026-02-04

HCQ in Resectable Localized Prostate Cancer

Dartmouth-Hitchcock Medical Center

Phase EARLY_PHASE1 Recruiting
20 enrolled
Genitourinary

Resectable Localized Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡